[89Zr]girentuximab PET Identifies Any Renal Malignancy with 98% Positive Predictive Value

The rising incidence of incidentally detected small renal masses presents a persistent clinical dilemma, as conventional cross-sectional imaging often fails to distinguish between benign lesions and aggressive malignancies [1, 2]. While up to 25% of these masses are eventually found to be benign, the lack of highly specific non-invasive tools frequently leads to unnecessary surgical interventions and associated morbidity [2, 3]. Molecular imaging has emerged as a potential solution to this diagnostic gap, utilizing targeted radiotracers to visualize specific tumor biomarkers like carbonic anhydrase IX and the prostate-specific membrane antigen [4, 5]. Recent advancements in immuno-positron emission tomography (a technique using antibody-based radiotracers to map specific protein expression) have focused on identifying clear cell renal cell carcinoma, the most common and aggressive subtype, by targeting its unique metabolic and surface protein expressions [6, 7]. A new analysis of the ZIRCON trial now provides critical evidence regarding the ability of these targeted tracers to identify a broader spectrum of renal malignancies than previously recognized, potentially shifting the diagnostic focus from a single histological subtype to a more comprehensive assessment of renal cancer.